m+Medelevator.RU
← Поиск публикаций
Molecular cell · 2025

SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ogawa Akane, Izumikawa Keiichi, Tate Sota, Isoyama Sho, Mori Masaru, Fujiwara Kohei, Watanabe Soyoka, Ohga Takayuki, Jo Ukhyun, Taniyama Daiki, Kitajima Shojiro, Tanaka Soichiro, Onji Hiroshi, Kageyama Shun-Ichiro, Yamamoto Gaku, Saito Hitoshi, Morita Tomoko Yamamori, Okada Masayasu, Natsumeda Manabu, Nagahama Masami, Kobayashi Junya, Ohashi Akihiro, Sasanuma Hiroyuki, Higashiyama Shigeki, Dan Shingo, Pommier Yves, Murai Junko

Аннотация

Impairment of ribosome biogenesis (RiBi) triggered by inhibition of ribosomal RNA (rRNA) synthesis and processing leads to various biological effects. We report that Schlafen 11 (SLFN11) induces TP53-independent apoptosis through RiBi impairment. Upon replication stress, SLFN11 inhibits rRNA synthesis with RNA polymerase I accumulation and increased chromatin accessibility in the ribosomal DNA (rDNA) genes. SLFN11-dependent RiBi impairment preferentially depletes short-lived proteins, particularly MCL1, leading to apoptosis in response to replication stress. SLFN11's Walker B motif (E669), DNA-binding site (K652), dephosphorylation site for single-strand DNA binding (S753), and RNase sites (E209/E214) are all required for the SLFN11-mediated RiBi impairment. Comparable effects were obtained with direct RNA polymerase I inhibitors and other RiBi inhibitory conditions regardless of SLFN11. These findings were extended across 34 diverse human cancer cell lines. Thus, we demonstrate that RiBi impairment is a robust inactivator of MCL1 and an additional proapoptotic mechanism by which SLFN11 sensitizes cancer cells to chemotherapeutic agents.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты